BRAF and melanoma: The development of mutant BRAF and of MEK1/2 inhibitors has markedly improved treatment of advanced BRAF-mutant melanoma [1-2] showing highly significant effects on progression-free and/or overall survival in several phase III trials, in comparison to chemotherapy [3].